Monoclonal Antibody Therapies Against SARS-CoV-2: Promises and Realities
Author:
Publisher
Springer Berlin Heidelberg
Link
https://link.springer.com/content/pdf/10.1007/82_2024_268
Reference117 articles.
1. ACTIV-3/TICO LY-CoV555 Study Group (2020) A neutralizing monoclonal antibody for hospitalized patients with Covid-19. N Engl J Med 384(10):905–914. https://doi.org/10.1056/NEJMoa2033130
2. ACTIV-3: Therapeutics for Inpatients With COVID-19—Full Text View—ClinicalTrials.gov
3. Anderson TS, O’Donoghue A, Mechanic O, Dechen T, Stevens J (2022) Administration of anti–SARS-CoV-2 monoclonal antibodies after US food and drug administration deauthorization. JAMA Netw Open 5(8):e2228997-e. https://doi.org/10.1001/jamanetworkopen.2022.28997
4. AZD7442 reduced risk of developing severe COVID-19 or death in TACKLE Phase III outpatient treatment trial (2022). Accessed online at https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2021/azd7442-phiii-trial-positive-in-covid-outpatients.html on 22 Feb 2022
5. Benotmane I, Velay A, Thaunat O, Vargas GG, Olagne J, Fafi-Kremer S et al (2022) Pre-exposure prophylaxis with Evusheld™ elicits limited neutralizing activity against the Omicron variant in kidney transplant patients. Kidney Int 22(S0085–2538):00383. https://doi.org/10.1016/j.kint.2022.05.008
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3